US-based biotech company eFFECTOR Therapeutics has secured $38.6m in a series C venture financing round led by Pfizer Venture Investments (PVI).

The company plans to use the funds to progress the development of its MNK1/2 inhibitor, eFT508, into Phase II development.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

VenatoRx Pharmaceuticals has secured $42m in a series B venture financing round led by Versant Venture Management.

"VenatoRx Pharmaceuticals has secured $42m in a series B venture financing round led by Versant Venture Management."

The US-based biopharmaceutical company plans to use the funds for the development of its product portfolio.

Kezar Life Sciences, a biopharmaceutical company based in the US, has secured $50m in a series B venture financing round led by Cormorant Asset Management.

See Also:

The company will direct the funds towards the development of its immunoproteasome inhibitor KZR-616.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.